BE with 1 not included in CI -danish twist [RSABE / ABEL]

posted by bjkim97  – Korea / Seoul, 2013-02-06 06:56 (4480 d 21:42 ago) – Posting: # 9969
Views: 5,163

❝ Dear d_labes!



❝ If your study is aimed for the European market no go! The widest acceptance range allowed in the EMA guidance is 69.84% ... 143.19% given that your study is a replicate crossover study and your intra-subject CV of the Reference from that study is >=50%. Note that the widening is only allowed for Cmax.


Why this CV(Intra) is >=50%?
Is this CV(Intra)>=30%?. Is not that widening is more than >=30%?

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,671 registered users;
123 visitors (0 registered, 123 guests [including 13 identified bots]).
Forum time: 05:38 CEST (Europe/Vienna)

Don’t undertake a project
unless it’s manifestly important
and nearly impossible.    Edwin H. Land

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5